More about
Her2-Positive/Hr-Positive Metastatic Breast Cancer
News
December 28, 2023
2 min read
Save
Combination yields ‘promising PFS outcomes’ in certain patients with breast cancer
SAN ANTONIO — The combination of zanidatamab, palbociclib and fulvestrant yielded promising PFS results among adults with HER2-positive/hormone receptor-positive metastatic breast cancer, findings from a phase 2A study showed.